|
WO2021072307A1
|
|
Solid state crystalline forms of a selective potassium channel modulator
|
|
CA3110853A1
|
|
Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
|
|
WO2020047312A1
|
|
Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
|
|
CA3106031A1
|
|
Method for treating epilepsy
|
|
KR20210019507A
|
|
Benzenesulfonamide compounds and their use as therapeutic agents
|
|
KR20210020892A
|
|
Method to improve bioavailability and exposure of voltage dependent potassium channel openers
|
|
AU2017283651A1
|
|
Solid state forms of spiro-oxindole compounds
|
|
SG10201912216VA
|
|
Benzenesulfonamide compounds and their use as therapeutic agents
|
|
CA3042004A1
|
|
Benzenesulfonamide compounds and their use as therapeutic agents
|
|
AU2015224493A1
|
|
Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
|
|
AU2014265116A1
|
|
Spiro-oxindole compounds and their use as therapeutic agents
|
|
WO2014018375A1
|
|
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
|
AU2013206248A1
|
|
Organic compounds
|
|
AU2013246485A1
|
|
Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
|
|
WO2013064984A1
|
|
Biaryl ether sulfonamides and their use as therapeutic agents
|
|
CA2853439A1
|
|
Benzenesulfonamide compounds and their use as therapeutic agents
|
|
IL219194D0
|
|
Synthetic methods for spiro-oxindole compounds
|
|
WO2011106729A2
|
|
Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
|
|
JP2011052022A
|
|
Nicotinamide derivative as therapeutic agent and use thereof
|
|
AU2010306768A1
|
|
Synthetic methods for spiro-oxindole compounds
|
